RET and non-small cell lung carcinoma: Selpercatinib was investigated in the open-label phase I/II LIBRETTO-001 trial, in which 105 pretreated (with at least one platinum doublet chemotherapy) and 39 naïve RET+ advanced NSCLC patients received selpercatinib in monotherapy.